IDH2 and acute myeloid leukemia: Enasidenib, an inhibitor of IDH-2, is FDA-approved for the treatment of relapsed/refractory AML patients who harbor a sensitizing IDH-2 mutation, with a response rate of nearly 40 percent in this setting [77], although this drug is not currently approved in Canada or Europe.